Table 1 Univariate and multivariate Cox regression analysis of the gene signature and disease-free survival of NSCLC patients

GSE31210

 Age

≤ 65/> 65

176/50

1.89 (1.12–3.18)

1.70E−02

2.36 (1.37–4.04)

1.83E−03

 Gender

Female/male

121/105

1.27 (0.78–2.07)

3.38E−01

 ALK fusion

+/−

215/11

0.74 (0.18–3.02)

6.73E−01

 EGFR mutation

+/−

99/127

0.60 (0.37–0.98)

4.29E−02

1.98 (0.88–4.47)

1.00E−01

 KRAS mutation

+/−

206/20

0.98 (0.42–2.26)

9.56E−01

 Triple negative

No/yes

158/68

1.87 (1.14–3.08)

1.39E−02

2.91 (1.30–6.54)

9.71E−03

 Myc copy

Low/high

207/17

1.04 (0.42–2.59)

9.33E−01

 Stage

I/II

168/58

3.16 (1.92–5.21)

6.09E−06

2.77 (1.63–4.71)

1.62E−04

 Smoking

No/yes

115/111

1.33 (0.82–2.18)

2.52E−01

 Risk score

Low/high

123/103

3.26 (1.92–5.53)

1.24E−05

3.10 (1.77–5.41)

7.17E−05

GSE37745

 Age

≤ 65/> 65

45/51

0.89 (0.50–1.55)

6.70E−01

 Gender

Female/male

46/50

1.01 (0.58–1.78)

9.60E−01

 Stage

I/II

63/18

1.13 (0.54–2.38)

7.45E−01

 Stage

I/III

63/14

1.78 (0.81–3.91)

1.48E−01

 Stage

I/IV

63/1

5.71 (0.75–43.63)

9.32E−02

 Histological type

Adeno/large

53/13

1.05 (0.46–2.42)

9.08E−01

 Histological type

Adeno/squamous

53/30

1.12 (0.60–2.10)

7.17E−01

 WHO performance status

0/1

54/32

2.21 (1.21–4.03)

1.02E−02

2.43 (1.32–4.47)

4.31E−03

 WHO performance status

0/2

54/6

1.04 (0.25–4.42)

9.52E−01

1.12 (0.26–4.75)

8.77E−01

 WHO performance status

0/3

54/4

1.66 (0.50–5.53)

4.08E−01

1.62 (0.49–5.38)

4.34E−01

 Risk score

Low/high

46/50

2.31 (1.27–4.21)

6.08E−03

2.49 (1.36–4.55)

3.10E−03

GSE50081

 Age

≤ 65/> 65

59/118

1.24 (0.69–2.24)

4.77E−01

 Gender

Female/male

81/96

1.68 (0.95–2.99)

7.59E−02

 Stage

I/II

124/53

1.87 (1.06–3.28)

3.03E−02

1.71 (0.97–3.01)

6.30E−02

 Histological type

Adeno/large

124/7

1.04 (0.25–4.31)

9.59E−01

 Histological type

Adeno/squamous

124/42

0.73 (0.10–5.36)

7.61E−01

 Histological type

Adeno/other

124/4

0.74 (0.38–1.45)

3.79E−01

 Smoking

No/yes

24/133

0.70 (0.35–1.40)

3.14E−01

 Risk score

Low/high

83/94

2.42 (1.33–4.43)

4.02E−03

2.30 (1.26–4.22)

6.97E−03

All patients

 Age

≤ 65/> 65

280/219

1.36 (1.00–1.84)

5.04E−02

 Gender

Female/male

248/251

1.31 (0.96–1.78)

8.51E−02

 Stage

I/II

355/129

2.05 (1.47–2.85)

2.02E−05

1.72 (1.23–2.40)

1.50E−03

 Stage

I/III

355/14

3.45 (1.68–7.11)

7.74E−04

2.62 (1.27–5.43)

9.41E−03

 Stage

I/IV

355/1

22.26 (3.01–164.44)

2.36E−03

14.79 (2.00–109.7)

8.40E−03

 Histological type

Adeno/large

403/20

1.48 (0.75–2.93)

2.61E−01

 Histological type

Adeno/squamous

403/72

0.76 (0.11–5.44)

7.85E−01

 Histological type

Adeno/other

403/4

1.17 (0.77–1.78)

4.52E−01

 Risk score

Low/high

252/247

2.7 (1.94–3.76)

4.16E−09

2.39 (1.70–3.35)

4.47E−07